Research
Energy balance
Among patients who discontinued treatment, 72% did not demonstrate weight regain.
Clinicians may find that many patients can maintain weight after stopping GLP-1RA therapy.
StrongSupportsmedium confidence
Among these 119 patients, a similar pattern of weight trajectories was observed, with 72% of patients not demonstrating weight regain.
Why this rating
Based on the analysis of a specific subset of 119 patients.
Source
Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network
Karthik Murugadoss et al. · Biology Methods and Protocols · 2026
DOI 10.1093/biomethods/bpag020
cohort · n=4182
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Approximately two-thirds of patients showed stable weight or continued weight loss during the 6 months following their last semaglutide or tirzepatide prescription.Strong
- Exercise counseling was documented more frequently among patients with durable weight loss after the last GLP-1RA prescription than among those with weight regain (26.2% vs. 14.7%; P = .04).Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →